Thus, the genetic linker DOPA-encoded protein-drug (RBDdopa-BTZ) conjugate selectively targets ACE2-overexpressing NSCLC cells and releases BTZ through receptor-mediated endocytosis (Fig. 7). This evidence concerns the gene ACE2 and non-small cell lung carcinoma.